Adipotide

Adipotide is unlike anything else in the weight loss world. Instead of suppressing your appetite or speeding up your metabolism, it kills fat cells by cutting off their blood supply. The compound, also known as FTPP (Fat-Targeted Proapoptotic Peptide) or Prohibitin-TP01, targets the blood vessels that feed your white fat tissue and causes those vessels to die. When the blood supply is cut, the fat cells starve and undergo programmed cell death. It is the same basic strategy that cancer researchers have used to try to starve tumors, applied instead to fat tissue.

The preclinical results were remarkable. Obese mice lost around 30% of their body weight in just 4 weeks. Obese rhesus monkeys lost up to 39% of their body weight with improved metabolic markers. These numbers are dramatic even by the standards of the most powerful modern weight loss drugs. A Phase 1 human trial was started in 2011 in patients with advanced prostate cancer who also had obesity, but clinical development appears to have been discontinued as of 2019, and very limited information about human results has been made publicly available.

The fundamental difference between adipotide and everything else is that it actually destroys fat cells rather than just shrinking them. Most weight loss approaches, whether through diet, exercise, or medications, make fat cells smaller but leave them intact. Those cells can fill back up when you eat more. Adipotide removes the cells entirely, which in theory could produce more permanent fat loss. However, this same mechanism is what creates the compound's primary safety concern: destroying blood vessels anywhere in the body carries inherent risk, and the targeting is not perfect.

Adipotide is essentially a two-part molecular weapon. The first part is a targeting sequence that acts like a homing device. It locks onto specific proteins called prohibitin and ANXA2 that are found on the surface of the blood vessels feeding your white fat tissue. These proteins are abundant on the endothelial cells, which are the cells that line blood vessels in fat tissue, but they are less common on blood vessels elsewhere in the body. This targeting is what allows adipotide to preferentially attack fat tissue rather than other organs.

Once adipotide binds to its target on a fat-feeding blood vessel, the second part of the molecule goes to work. This killing sequence triggers apoptosis, which is the scientific term for programmed cell death, in the endothelial cells of those blood vessels. As the blood vessels are destroyed, the fat cells they were supplying lose their access to oxygen and nutrients. Without that lifeline, the fat cells die too. Think of it like cutting the supply lines to a city: without food and water coming in, the city cannot survive. The fat tissue withers because it has been starved of everything it needs.

The trade-off is that this targeting is not perfect. Blood vessels throughout your body share some of the same surface proteins, and the kidneys are particularly vulnerable because they are extremely rich in blood vessels. In primate studies, the most consistent side effect was mild, reversible kidney injury. The kidney stress was dose-dependent and went away after treatment stopped, but it highlights the inherent risk of a compound designed to destroy blood vessels. This imperfect targeting is likely a major factor in why clinical development was discontinued.